Italfarmaco
A specialty pharmaceutical company engaged in the discovery, development, manufacturing and marketing of branded prescription and nonprescription products in more than 60 countries on five continents.
Italfarmaco Group’s research and development expertise is best demonstrated through its HDAC inhibitor development programs, addressing new therapeutic treatments of specialty and rare diseases.
Latest Italfarmaco News & Features
22 March 2024
20 March 2024
5 September 2023
29 June 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze